Centiva Capital LP Lowers Stock Position in Mural Oncology plc (NASDAQ:MURA)

Centiva Capital LP trimmed its holdings in Mural Oncology plc (NASDAQ:MURA) by 9.3% during the third quarter, HoldingsChannel.com reports. The fund owned 203,706 shares of the company’s stock after selling 20,825 shares during the period. Centiva Capital LP’s holdings in Mural Oncology were worth $638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Rhumbline Advisers acquired a new position in Mural Oncology in the 2nd quarter valued at about $34,000. BBR Partners LLC purchased a new position in shares of Mural Oncology in the 2nd quarter valued at approximately $31,000. Acadian Asset Management LLC acquired a new position in shares of Mural Oncology in the second quarter valued at approximately $998,000. Nicollet Investment Management Inc. purchased a new stake in shares of Mural Oncology during the second quarter worth approximately $308,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Mural Oncology during the second quarter worth $71,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Mural Oncology Price Performance

Mural Oncology stock opened at $4.05 on Friday. The stock’s 50 day moving average price is $3.56 and its 200 day moving average price is $3.38. Mural Oncology plc has a 1-year low of $2.88 and a 1-year high of $6.25. The company has a market cap of $68.93 million and a PE ratio of -0.44.

Insiders Place Their Bets

In other news, CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the transaction, the chief financial officer now owns 71,438 shares in the company, valued at $243,603.58. This trade represents a 9.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MURA. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a research note on Monday, November 11th. Raymond James started coverage on shares of Mural Oncology in a report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.